Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Summary

The study will assess pharmacokinetic (PK) comparability between different formulations of AZD7442, which is a combination of two individual monoclonal antibodies (mAbs), AZD8895 and AZD1061.

Timeline

Start

2021-11-30

Primary completion

2023-07-19

Completion

2023-07-19

Publications

• Zhang H, Tang W, Sadow S, Baronio R, Tullio AN, Hirao L, Dzutseva V, Chen CC, Kiazand A, Chang LJ, Cohen TS, Gibbs M. Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve. Clin Pharmacokinet. 2026 May;65(5):747-761. doi: 10.1007/s40262-026-01631-7. Epub 2026 Mar 31.

Drugs

Indications